MacroGenics (MGNX)
(Real Time Quote from BATS)
$3.42 USD
-0.41 (-10.71%)
Updated Aug 5, 2024 10:48 AM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Brokerage Reports
MacroGenics, Inc. [MGNX]
Reports for Purchase
Showing records 61 - 80 ( 362 total )
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Acute Myeloid Leukemia: Current Treatment and Therapies in Development
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
HEALTHCARE - The Week Ahead in Life SciencesThis report contains brief updates on the following: BMRN, VYGR, AQST, AXLA, ICPT, IMUX, VRNA, BPMC, MGNX. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
2Q20 Update: First Look at MGD019 at the ESMO
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
MGC018-Associated PSA Responses Are Rapid and Dramatic
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: MacroGenics, Inc.
Industry: Medical - Products
Company: MacroGenics, Inc.
Industry: Medical - Products
ASCO Highlights: Full Steam Ahead for MGD013 and MGC018
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D